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ABSTRACT
The p53/MDM2 interaction has been a well-studied target for new drug design 
leading to the development of the small molecule inhibitor Nutlin-3. Our objectives 
were to combine Nutlin-3 with cisplatin (CDDP), a well-known activator of the p53 
pathway, in a series of non-small cell lung cancer cell lines in order to increase the 
cytotoxic response to CDDP. We report that sequential treatment (CDDP followed by 
Nutlin-3), but not simultaneous treatment, resulted in strong synergism. Combination 
treatment induced p53’s transcriptional activity, resulting in increased mRNA and 
protein levels of MDM2, p21, PUMA and BAX. In addition we report the induction of a 
strong p53 dependent apoptotic response and induction of G2/M cell cycle arrest. The 
strongest synergistic effect was observed at low doses of both CDDP and Nutlin-3, 
which could result in fewer (off-target) side effects while maintaining a strong 
cytotoxic effect. Our results indicate a promising preclinical potential, emphasizing 
the importance of the applied treatment scheme and the presence of wild type p53 
for the combination of CDDP and Nutlin-3.
INTRODUCTION
In recent years, cancer therapy has evolved 
from general treatment strategies to more specific 
targeted therapies, based on the genetic profile of 
individual tumors. Important progress has been made in 
understanding the underlying molecular mechanisms that 
drive tumorigenesis. These new findings have led to the 
discovery of new therapeutic targets, and consequently the 
development of new-targeted therapeutics. These tailor-
made treatment modalities might improve the efficiency of 
cancer treatment, reduce common side effects by avoiding 
unnecessary toxicity and improve general outcome. 
Preclinical studies have become increasingly important 
in this setting. They allow to determine new combination 
strategies of these targeted agents with conventional 
chemo- and/or radiotherapeutics, but also to unravel 
the underlying molecular mechanisms and to define the 
optimal treatment schemes. 
A well-know mechanism driving tumor formation 
is the disruption of the tumor suppressor protein p53. 
The protein plays an important role in the response to a 
variety of cellular stress signals by the induction of cell 
cycle arrest, senescence or apoptosis. The p53 pathway is 
disturbed in most cancers either by inactivating mutations, 
which occur in approximately 50% of all tumors, or by 
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other mechanisms, suppressing p53 levels in the cancer 
cell. This makes the altered p53 pathway an attractive 
target for novel cancer therapies [1-5]. 
An interesting strategy is to target the interaction 
between p53 and its main negative regulator, the ‘murine 
double minute-2’ (MDM2) protein. MDM2 is part of a 
negative feedback loop in which p53 acts as a transcription 
factor for MDM2, that in turn acts as an E3 ubiquitin ligase 
targeting p53 for proteasomal degradation. Overexpression 
of MDM2 interrupts the well-controlled balance between 
p53 and MDM2, leading to malignant transformation of 
the cell. Increased MDM2 levels can result from MDM2 
gene amplification, which is assumed to occur in 10% 
of human tumors [6], or from the presence of a single 
nucleotide polymorphism (SNP309) in the promoter 
region of the MDM2 gene [7]. Inhibiting the interaction 
between p53 and MDM2 might therefore restore the 
normal p53 function. In 2004, Vassilev et al. identified 
Nutlin-3, a small molecule inhibitor of the MDM2-p53 
interaction with in vitro and in vivo antitumor activity 
[8]. The molecule is able to induce the activation of p53 
downstream targets, cell cycle arrest and apoptosis [9]. 
Cancer cells with MDM2 gene amplification were most 
sensitive to Nutlin-3 in vitro and in vivo, but Nutlin-3 also 
showed good efficacy against tumors with normal MDM2 
expression. This shows that a wide array of patients with 
wild type p53 could benefit from the treatment with 
antagonists of the p53-MDM2 interaction [4]. 
Although Nutlin-3 shows a good efficiency as a 
single agent, the anti-tumoral effect might be enhanced 
when it is administered in combination with DNA-
damaging agents in p53 wild type tumors. In this study, 
we focused on the combination of Nutlin-3 with CDDP 
(cis-diamminedichloroplatinum(II); cisplatin), a well-
known activator of the p53 pathway, in a series of non-
small cell lung cancer (NSCLC) cell lines with different 
p53 background (Figure 1). We selected the commonly 
used A549 cell line based on its genotype (p53 wild 
type, EGFR/ALK/ROS1 negative) and suitability as 
transduction host, for which we used a vector containing 
anti-p53 specific shRNA. In addition, CRL-5908 was used, 
harboring the R273H p53 hotspot mutation, resulting in a 
conformational change in the p53 protein and inhibiting its 
transcriptional activity. Currently, CDDP treatment is used 
in platinum doublet therapy for the treatment of late stage 
EGFR/ALK/ROS1 negative tumors. However, tumor cells 
lacking functional p53 are prone to be more resistant to 
CDDP treatment [10]. Increasing functional p53 levels 
by Nutlin-3 could enhance the cytotoxic effect of CDDP. 
This combination regimen has been shown to be beneficial 
in both sarcoma cell lines and CDDP resistant ovarian 
cancer cell lines [9, 11]. On the other hand, Nutlin-3 
is able to protect both normal and tumor wild type p53 
cells from mitotic inhibitors like paclitaxel by inducing 
G1 and G2 phase arrest [12-15]. Therefore, we studied 
the effect of the treatment schedule for the combination 
of Nutlin-3 with CDDP by administrating these drugs 
either simultaneously or sequentially (CDDP followed by 
Nutlin-3). Prior treatment with Nutlin-3 would activate 
p53 in a non-genotoxic way resulting in cell cycle arrest 
rather than apoptosis; extending time for DNA repair 
mechanisms to take place in response to CDDP induced 
DNA damage before progression through critical phases 
of the cell cycle [16, 17]. Therefore, prior treatment with 
Nutlin-3 was not tested in this study. As regions with 
reduced oxygen levels often characterize tumors, a part 
of the study was performed under both normoxic and 
hypoxic (<0.1% O2) conditions.
RESULTS
The role of wild type p53 in the response to 
Nutlin-3 monotherapy
To determine the role of the p53 status in the 
cytotoxic effect of Nutlin-3, cells with a different p53 
background were treated with 0-50 μM Nutlin-3 for 24 
hours. The p53 wild type cell line A549 and its non-
template control A549-NTC were clearly more sensitive 
to Nutlin-3 (IC50: 17.68 ± 4.52 μM and 19.42 ± 1.96 μM, 
respectively), with an IC50 value significantly lower than 
the isogenic p53 deficient cell line A549-920 (33.85 ± 
4.84 μM; p-value: 0.002) and p53 mutant cell line CRL-
5908 (38.71 ± 2.43 μM; p-value < 0.001) (Figure 2A). To 
obtain a better insight in the underlying mechanisms, all 
cells were treated with 5 μM, 10 μM or 25 μM Nutlin-3 
(corresponding with the IC20, IC40 and IC60 value in the 
p53 wild type cell line A549) and p53 expression levels 
were assessed. In contrast to the p53 deficient or mutant 
cell lines, increasing p53 protein levels were observed 
in accordance with increasing levels of Nutlin-3 in the 
p53 wild type cell lines (Figure 2B). Lower levels of 
p53 and p21 were observed for CRL-5908 treated with 
10 μM Nutlin-3 due to a lower concentration of protein 
loaded, corresponding with β-actin control levels. Nutlin-3 
treatment led to the activation of wild type p53, resulting 
in increased protein levels of its main transcription targets 
PUMA, BAX, p21 and MDM2 (Figure 2B), which in turn 
led to a significant increase in annexin V positive cells 
(Figure 2C) in the p53 wild type cell lines, but not in the 
p53 deficient and mutant cell lines. A significant G2/M 
phase arrest was observed in A549 and A549-NTC at 25 
μM Nutlin-3 treatment, but also in the p53 deficient cell 
line A549-920, due to the presence of residual p53 and 
p21 protein. The p53 mutant cell line did not show any 
significant change in G2/M phase arrest (Figure 2D). 
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Figure 1: p53 pathway in response to CDDP and Nutlin-3 therapy. CDDP induces DNA damage by forming DNA cross-links, 
thereby inducing the activation of ATM/ATR. The latter are able to activate p53 by phosphorylation and the formation of a p53 tetramer, 
which acts as a transcription factor for among others MDM2 (negative regulation), BAX and PUMA (apoptosis) and p21 (cell cycle arrest). 
The inhibition of MDM2 by Nutlin-3 results in a high increase in p53 levels in response to CDDP treatment resulting in a synergistic 
cytotoxic effect. 
Figure 2: The response to Nutlin-3 monotherapy was strongest in the presence of wild type p53 A. Survival curve after 
24 hours of treatment with Nutlin-3 (0-50 μM) in the p53 wild type cell lines A549 and A549-NTC, the p53 deficient cell line A549-920 
and p53 mutant cell line CRL-5908. The corresponding IC50-values are presented as mean ± SD in the figure. B. Protein expression levels 
of p53 and its main transcription targets MDM2, p21, PUMA, and BAX after treatment with 0, 5, 10 or 25 μM Nutlin-3 in all cell lines. 
C. Percentage of Annexin V PerCP positive cells after 0, 5, 10 or 25 μM Nutlin-3 in all cell lines. D. Cell cycle distribution after Nutlin-3 
monotherapy, Cells were stained with Propidium Iodide and DNA content was measured by flowcytometric analysis. Cells were divided 
in 3 groups: G1 phase (2n); S-phase (2n-4n); and G2/M phase (4n). (*p < 0.05: significant difference compared to vehicle treated sample).
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Nutlin-3 strongly synergizes with CDDP after 
sequential combination therapy
Cell survival and synergism
To investigate the potential interaction between 
Nutlin-3 and CDDP in the p53 wild type NSCLC cell line 
A549, tumor cells were incubated with 0-20 μM CDDP 
combined with either simultaneous or sequential treatment 
of 0 μM, 5 μM, 10 μM or 25 μM Nutlin-3 for 24 hours. A 
clear difference was observed between the two treatment 
schemes, supported by the data in Table 1 and Figure 
3. After sequential treatment, the strongest synergistic 
effect was observed in the lowest concentrations ranges 
of both Nutlin-3 and CDDP (<CI> = 0.486 for CDDP 
-> 5 μM Nutlin-3) (Figure 3B), resulting in a significant 
reduction in CDDP IC50-value (6.28 ± 1.62 vs. 2.52 ± 0.57 
μM, p-value = 0.003). On the contrary, Nutlin-3 seemed 
to protect cells from the cytotoxic effect of medium 
to high concentrations of CDDP when administrated 
simultaneously, resulting in an antagonistic effect at higher 
concentrations of CDDP. However, a weak synergistic 
effect at low concentrations of both Nutlin-3 and CDDP 
(<CI> = 0.990 for CDDP + 5 μM Nutlin-3) was found 
(Figure 3A). 
The induction of a hypoxic environment led to a 
noticeable decrease in CDDP IC50-value when sequentially 
combined with 5 μM Nutlin-3, although not significant 
(6.73 ± 0.30 vs. 4.69 ± 0.85 μM, p-value = 0.100). In 
this hypoxic environment, sequential therapy induced a 
synergistic effect, yet slightly weaker than the synergism 
observed under normoxic conditions (<CI> = 0.625 vs. 
<CI> = 0.486). As hypoxic conditions did not inhibit the 
synergistic effect we conducted the following experiments 
under normal oxygen levels. 
Activation of wild type p53
The p53 protein levels strongly increased after 
sequential combination therapy, even at a low dose of 
Nutlin-3, compared to CDDP and Nutlin-3 monotherapy 
(Figure 4A). After simultaneous treatment this effect was 
only observed at higher concentrations of Nutlin-3.
Next, the activation status of p53 was determined 
by determining the mRNA and protein levels of its main 
transcription targets MDM2, PUMA, BAX, and p21 
as well as their downstream effects, namely apoptosis 
(PUMA and BAX) and cell cycle arrest (p21).
Figure 3: Survival curve and combination index (CI) of the sequential and simultaneous combination therapy in the 
p53 wild type cell line A549. A. 1. Survival curve after 24 hours of CDDP (0-20 μM) monotherapy and in simultaneous combination 
with 5 μM, 10 μM, or 25 μM Nutlin-3. 2. The corresponding combination index for each Nutlin-3 concentration is shown in detail on the 
right. Each data point represents the corresponding CDDP concentration (0.5-1-2-5-10-20 μM). B. 1. Survival curve after 24 hours of CDDP 
(0-20 μM) monotherapy and sequential combination therapy with 5 μM, 10 μM, or 25 μM Nutlin-3. 2. The corresponding combination 
index for each Nutlin-3 concentration is shown in detail on the right. Each data point represents the corresponding CDDP concentration 
(0.5-1-2-5-10-20 μM). The supporting data for this figure (Mean IC50-values and mean CI) can be found in Table 1. 
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Table 1: Cytotoxicity and synergism of the CDDP and Nutlin-3 combination therapy in the p53 wild type cell line A549. 
Cytotoxicity and synergism 
Treatment 	 Normoxia	(0-20	μM	CDDP)IC50 StDev p-value* CI StDev
24 h CDDP 5.51 0.66 / / /
24 h CDDP ->   5 μM Nutlin-3 2.67 0.26 0.003 0.486 0.138
24 h CDDP -> 10 μM Nutlin-3 5.46 0.37 0.788 0.752 0.174
24 h CDDP -> 25 μM Nutlin-3 9.13 2.70 0.003 1.050 0.108
24 h CDDP 6.35 2.30 / / /
24 h CDDP +   5 μM Nutlin-3 15.36 3.93 0.008 0.990 0.333
24 h CDDP + 10 μM Nutlin-3 22.39 7.63 0.008 1.000 0.296
24 h CDDP + 25 μM Nutlin-3 16.29 3.26 0.016 1.033 0.114
Treatment Hypoxia	(0-20	μM	CDDP)IC50 StDev p-value* CI StDev
24 h CDDP 6.73 0.30 / / /
24 h CDDP ->   5 μM Nutlin-3 4.68 0.85 0.100 0.625 0.082
24 h CDDP -> 10 μM Nutlin-3 5.72 0.77 0.200 0.792 0.116
24 h CDDP -> 25 μM Nutlin-3 6.62 1.46 0.629 0.975 0.211
24 h CDDP 6.29 0.89 / /  
24 h CDDP +   5 μM Nutlin-3 11.24 1.63 0.057 1.068 0.361
24 h CDDP + 10 μM Nutlin-3 15.86 5.59 0.029 1.076 0.330
24 h CDDP + 25 μM Nutlin-3 11.30 1.48 0.057 1.227 0.113
The table gives an overview of the IC50-value of CDDP after both monotherapy and simultaneous/sequential combination 
therapy with Nutlin-3 under normoxic or hypoxic conditions.  The average combination index (CI) is provided for each 
combination therapy. CI > 1 indicates an antagonistic effect, CI = 1 an additive effect and CI < 1 a synergistic effect. (* p < 
0.05: significant difference in IC50-value compared to CDDP monotherapy)
Figure	4:	Expression	of	the	p53	protein	and	its	negative	regulator	MDM2	after	simultaneous	and	sequential	combination	
therapy in the p53 wild type cell line A549. A. p53 protein levels after treatment B. MDM2 protein levels after treatment; β-actin was 
used as an internal standard. C. MDM2 mRNA levels after sequential treatment. D. MDM2 mRNA levels after simultaneous treatment. (*p 
< 0.05: significant difference compared to 0 μM CDDP; **p < 0.05: significant difference compared to 2 μM CDDP).
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Table 2: Overview of the IC50-values and CI obtained after sequential combination treatment for which 
CDDP	was	followed	by	Nutlin-3	in	the	p53	wild	type	cell	lines	A549	and	A549-NTC,	the	p53	deficient	cell	line	
A549-920 and p53 mutant cell line CRL-5908. 
The role of p53 on cytotoxicity and synergism
Cell line Nutlin-3 (μM)
CDDP	(0-20	μM)
IC50 StDev p-value* CI StDev
A549 0 5.51 0.66 / / /
-> 5 μM 2.67 0.26 0.003 0.486 0.138
A549-NTC 0 4.63 0.35 / / /
-> 5 μM 3.69 0.27 0.024 0.785 0.370
A549-920 0 8.72 0.86 / / /
-> 5 μM 9.23 1.91 0.421 1.906 2.147
CRL-5908 0 9.60 0.63 / / /
-> 5 μM 9.70 1.73 0.700 1.453 0.447
The average combination index (CI) is provided for each combination therapy. CI > 1 indicates an antagonistic effect, 
CI = 1 an additive effect and CI < 1 a synergistic effect. (* p < 0.05: significant difference in IC50-value compared to 
CDDP monotherapy)  
Figure 5: Nutlin-3 enhanced the apoptotic effect of CDDP in the p53 wild type cell line A549. A. Relative mRNA expression 
levels of p53’s main apoptotic targets PUMA and BAX. Cells were treated with either 2 μM CDDP; 5 μM, 10 μM or 25 μM Nutlin, or a 
sequential (CDDP -> Nutlin)/simultaneous combination therapy of both drugs for 24 hours. B. Corresponding protein levels of PUMA and 
BAX, β-actin was used as internal standard. C. Cells were labeled with Annexin V-FITC (AnnV) and Propidium Iodide (PI) and measured 
by flowcytometric analysis. Dot-plot: LL = AnnV-/PI-; LR = AnnV+/PI-; UR = AnnV+/PI+; UL = AnnV-/PI+. D. Percentage of Annexin 
V FITC positive cells. (*p < 0.05: significant difference compared to 0 μM CDDP; **p < 0.05: significant difference compared to 2 μM 
CDDP).
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Negative	regulation:	induction	of	MDM2
The mRNA levels of MDM2 were markedly 
increased after sequential treatment, but not after 
simultaneous treatment, compared to both CDDP and 
Nutlin-3 monotherapy (Figure 4C) although a statistically 
significant increase was only observed when CDDP was 
combined sequentially with 25 μM Nutlin-3 (Figure 4C, 
Figure 4D). At the MDM2 protein level, a noticeable 
increase was seen earlier with a lower dose of Nutlin-3 
(5 μM) for the sequential treatment compared to 
simultaneous treatment. At higher doses of Nutlin-3, no 
difference was seen between sequential and simultaneous 
treatment (Figure 4B). 
Induction of apoptosis
Treatment with Nutlin-3 led to a moderate (5 μM 
and 10 μM) to significant (25 μM) increase in PUMA 
mRNA levels. A similar effect was observed after 
simultaneous and sequential combination therapy, for 
which a significant effect was observed after treatment 
with 10 and 25 μM Nutlin-3 in combination with 2 µM 
CDDP (Figure 5A). This effect was translated to the 
PUMA protein levels (Figure 5B). Despite these similar 
effects after simultaneous and sequential therapy, a 
significant increase in BAX mRNA levels was observed 
only after sequential combination therapy, but not after 
monotherapy or simultaneous combination therapy (Figure 
5A). Again, this was also reflected at the BAX protein 
levels (Figure 5B).
As both PUMA and BAX are able to induce p53 
dependent apoptosis, the percentage of Annexin V 
positive cells and PI positive cells was determined (Figure 
5C). Sequential treatment led to a significant increase 
in Annexin V positive cells even at low concentration 
Figure	6:	Nutlin-3	induced	a	strong	G2/M	phase	arrest	in	combination	with	CDDP	in	the	p53	wild	type	cell	line	A549	
A. Relative mRNA expression levels of p53’s transcription target p21. Cells were treated with either 2 μM CDDP; 5 μM, 10 μM or 25 μM 
Nutlin-3, or a sequential (CDDP –> Nutlin)/simultaneous combination therapy of both drugs for 24 hours. B. Corresponding p21 protein 
levels, β-actin was used as internal standard. C. Cell cycle distribution of treated cells. Cells were stained with PI and DNA content was 
measured by flowcytometric analysis. Cells were divided in 3 groups: G1 phase (2n); S-phase (2n-4n); and G2/M phase (4n). (*p < 0.05: 
significant diffence compared to 0 μM CDDP; **p < 0.05: significant difference compared to 2 μM CDDP).
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of Nutlin-3 (5 μM), which was not observed after 
simultaneous or CDDP/Nutlin-3 monotherapy treatment 
(Figure 5D). 
Cell cycle distribution
P21 is an important transcription target of p53, able 
to induce cell cycle arrest. The mRNA levels of p21 were 
determined after both mono- and combination therapy. A 
strong and significant increase in p21 mRNA levels was 
observed after monotherapy with 25 μM Nutlin-3, and 
after sequential treatment with 5, 10 and 25 μM Nutlin-3 
(Figure 6A). Again, a significant effect was not present 
after simultaneous treatment (Figure 6A). Similarly, the 
highest levels of the p21 protein were observed after 
sequential combination therapy (Figure 6B). 
Since therapy seemed to induce a strong 
activation of the downstream target p21, the cell cycle 
distribution after both mono- and combination therapy 
was investigated, resulting in a very strong significant 
G2/M phase arrest after sequential therapy, even at 
low concentrations of Nutlin-3 and a markedly but not 
significant increase after monotherapy and simultaneous 
combination therapy (Figure 6C). Again, the sequential 
combination therapy was clearly more favorable over 
monotherapy or simultaneous combination therapy. 
Therefore, for the following experiments we focused on 
the sequential combination therapy. 
Duration of the cytotoxic effect
By monitoring the proliferation rate of A549 in real-
time using the xCELLigence system, a better insight in 
the duration and persistence of the cytotoxic effect after 
sequential treatment has been acquired. Figure 7A shows 
the growth curve after sequential treatment with CDDP 
followed by Nutlin-3. All curves were normalized at the 
end of treatment 1 (24h CDDP). Figure 7B shows the 
corresponding cell survival at 1, 6, 12, 48, 72, 96 and 
120 hours after the start of treatment 2 (24h Nutlin-3). 
Treatment with 2 μM CDDP had only a minor effect 
on overall cell survival over time. On the other hand, 
treatment with 5 μM Nutlin-3 showed an increase of the 
cell index in the first 48 hours after the start of treatment, 
after which the number of cells gradually decreased. 
Sequential combination therapy showed a substantial 
decrease in the number of cells compared to the vehicle 
treated sample starting within 6 hours after treatment 
with Nutlin-3. After 96 hours, this decrease stagnated. 
These results indicate that the cytotoxic effect is clearly 
dependent on the addition of Nutlin-3, and is persistent 
over time, up to 96 hours after wash out of the drugs. 
Figure 7: Real-time cell-viability of A549 by using the xCELLigence system after sequential treatment with CDDP and 
Nutlin-3. A. Normalized cell index over time after mono- and sequential combination therapy. B. Percentage of cell survival x hours after 
the start of treatment 2 (Nutlin-3). 
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The role of wild type p53
To determine the role of wild type p53 in the 
observed cytotoxic effect of the synergistic combination 
therapy (2 μM CDDP treatment followed by 5 μM 
Nutlin-3), a similar experimental setup was used for the 
A549 non-template control (A549-NTC), p53 deficient 
(A549-920) and p53 mutant cell line (CRL-5908). All cell 
lines were compared to the wild type p53 cell line A549. 
There was no significant difference between the 
CDDP IC50-values in A549 and A549-NTC cells (IC50: 
5.51 ± 0.72 vs. 4.63 ± 0.39, p-value = 0.066), while the 
p53 deficient cell line A549-920 was significantly less 
sensitive to CDDP (IC50: 8.72 ± 0.86, p-value = 0.000) as 
for the p53 mutant cell line CRL-5908 (IC50: 9.60 ± 0.63, 
p-value = 0.000) compared to A549 (table 2). A strong 
to moderate synergistic effect was only observed in the 
p53 wild type cell line A549 and A549-NTC (CI = 0.486 
± 0.138; CI = 0.785 ± 0.370, respectively), which was 
strongest at low concentrations of CDDP. A549-920 was 
characterized by an overall antagonistic effect, but slightly 
synergistic at certain CDDP concentrations (CI = 1.906 
± 2.147). For CRL-5908 cells, no synergistic effect was 
observed at any CDDP concentration (CI = 1.453 ± 0.447). 
A more detailed overview of these results is given in Table 
2 and Figure 8A. 
Next, the p53 protein levels were studied. The 
strongest increase was observed after combination therapy 
in the p53 wild type cell lines. The transduced A549-
920 cell line expressed some residual levels of p53 after 
CDDP and combination therapy, but markedly lower than 
the parental cell line A549 and its negative control A549-
NTC. CRL-5908 showed high levels of mutant p53, which 
were strongest after CDDP treatment and independent of 
Nutlin-3 treatment (Figure 8B).
Corresponding with the p53 levels, the protein levels 
of p53’s main transcription targets (MDM2, PUMA, BAX 
and p21) increased in the p53 wild type cell lines, with 
the most noticeable increase after combination therapy. 
None of these targets were observed in the p53 mutant 
cell line CRL-5908. As mentioned before, A549-920 
cells expressed some residual p53 protein, resulting in 
an increased expression of MDM2 and p21 after CDDP 
treatment or combination therapy, but not after Nutlin-3 
monotherapy. This effect in A549-920 was much less 
pronounced for the apoptotic related proteins PUMA, for 
which no increase was observed after combination therapy, 
and BAX, whose levels slightly increased after CDDP 
and combination therapy (Figure 8B). In the same way, 
combination therapy influenced the cell cycle distribution 
dependent on the p53 status of the cell. The wild type p53 
cell lines A549 and A549-NTC, but also the p53 deficient 
cell lines A549-920 responded by a significant G2/M 
phase arrest. However, the arrest induced in A549-920 was 
significantly less than this induced in the parental cell line 
A549 (p = 0.015). The p53 mutant cell line did not show 
any significant changes in cell cycle distribution (Figure 
8D). Finally, the induction of apoptosis was similarly 
dependent on the p53 status of the cell. A significant 
increase in apoptotic cells was only observed in the p53 
wild type cell lines, but not in the p53 mutant and deficient 
cell line. Nevertheless, the A549-920 cell line did show an 
identifiable increase in apoptotic cells (Figure 8C). 
DISCUSSION
CDDP is the first line treatment for a selected 
NSCLC patient population administrated as platinum 
doublet therapy. The induction of CDDP dependent DNA 
damage triggers the DNA damage response activated by 
the ATR-Chk2 pathway resulting in p53 activation and 
apoptosis [18]. Tumor cells lacking functional p53 were 
more resistant to CDDP therapy, which was reversed upon 
reconstitution with wild type p53 [10]. In addition, TP53 
mutations seem to negatively influence the response to 
CDDP therapy as a significant better overall survival and 
response rate was observed in TP53 wild type patients 
compared to TP53 mutant patients [19-21]. As the p53 
pathway clearly plays an important role in the response 
to CDDP, the presence of adequate levels of functional 
wild type p53 is a necessity. By targeting the MDM2-p53 
interaction in wild type p53 tumors, the p53 levels can be 
increased and the cytotoxic response to CDDP might be 
improved. 
In this study, we hypothesized that the combination 
of CDDP with the MDM2 inhibitor Nutlin-3 could result 
in a synergistic cytotoxic response in p53 wild type cell 
lines. We focused on the sequence of administration, since 
Nutlin-3 is able to induce cell cycle arrest, which possibly 
could protect the cells from CDDP damage. Consistent 
with previous studies, our study showed that the response 
to Nutlin-3, in particular the induction of apoptotic cell 
death and cell cycle arrest, is p53 dependent, as only a 
minor cytotoxic effect was observed in the p53 deficient 
and mutant cell lines at high concentrations of Nutlin-3 [9, 
22, 23]. Although the p53 wild type cells were sensitive 
to Nutlin-3 monotherapy, the apoptotic response and 
induction of cell cycle arrest were limited, possibly due 
to the lack of an activation signal of the p53 pathway, 
for example the induction of DNA damage by CDDP 
treatment. 
This hypothesis was confirmed in our results 
indicating that the cytotoxic effect of CDDP was 
synergistically increased when combined with Nutlin-3. 
Our results are similar to those of previous studies in 
CDDP sensitive and resistant ovarian cancer cell lines 
or sarcoma cell lines, in which a low dose of CDDP 
was combined simultaneously with Nutlin-3 [9, 11]. 
We are the first to show that the sequential treatment of 
CDDP followed by Nutlin-3 resulted in the most potent 
synergistic effect compared to simultaneous treatment, 
both under normoxic and hypoxic conditions, in NSCLC. 
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This effect was reflected at both the p53 protein level as 
well as its activity. Treatment resulted in a significant 
increase in p53’s transcriptional targets at both mRNA 
and protein level and the resulting induction of G2/M 
cell cycle arrest and apoptotic cell death. In this study 
we looked at the expression levels of the pro-apoptotic 
proteins PUMA and BAX. PUMA localizes to the 
mitochondria and inhibits the anti-apoptotic proteins 
Bcl-2 and Bcl-XL, resulting in BAX activation. BAX 
is a transcriptional target of p53 and is able to induce 
mitochondrial outer membrane permeabilization, resulting 
in the release of cytochrome c and induction of apoptotic 
caspase pathway [24]. For PUMA mRNA levels, similar 
results were observed after simultaneous versus sequential 
treatment although protein levels differed. On the contrary 
BAX mRNA levels were only significantly increased after 
sequential therapy, which resulted in a strong difference 
in BAX protein levels, compared to simultaneous therapy. 
The capability of sequential treatment to induce a stronger 
BAX upregulation might explain the difference seen in the 
apoptotic response between simultaneous and sequential 
combination therapy. 
In addition, drug dose largely affected synergism. 
Although combination treatment with higher doses of 
Nutlin-3 resulted in an increased transcription of p53 
target genes and consequently increased protein levels, 
this did not result in a stronger synergistic effect. Adequate 
levels of p53 protein and its target proteins to induce their 
effect on cell cycle distribution or apoptosis seem to be 
reached at the combination of low doses. This effect was 
not improved by augmenting the dose of Nutlin-3 as seen 
in Figures 5 and 6. This could explain why the synergistic 
effect was strongest at low doses of CDDP and Nutlin-3. 
The reduction of this response in the p53 deficient 
cell line, that still expressed low levels of p53, and the 
absence of a response in the mutant cell line indicates 
Figure 8: The synergistic cytotoxic effect of the sequential combination therapy was correlated with the p53 status of 
the cell. A. Combination index for each CDDP concentration after sequential combination therapy in the p53 wild type cell lines A549, 
A549-NTC, the p53 deficient cell line A549-920 and the p53 mutant cell line CRL-5908. The supporting data for this figure (Mean IC50-
values and mean CI) can be found in table 2. B. Protein expression levels of p53 and its main transcription targets MDM2, p21, PUMA, 
and BAX after monotherapy with CDDP or 5 μM Nutlin-3 or sequential combination therapy in each cell line. C. Percentage of Annexin 
V PerCP positive cells after treatment in all cell lines, measured by flowcytometric analysis D. Cell cycles distribution after treatment as 
previously described in all cell lines. Cells were stained with PI and DNA content was measured by flowcytometric analysis. Cells were 
divided in 3 groups: G1 phase (2n); S-phase (2n-4n); and G2/M phase (4n). (*p < 0.05: significant difference compared to 0 μM CDDP; 
**p < 0.05: significant difference compared to 2 μM CDDP).
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that this effect is strongly p53 dependent, implicating that 
only patients harboring wild type p53 would benefit from 
this combination. However, newly developed molecules 
like APR-246 (reactivation of mutant p53) could be able 
to overcome this limitation [25]. The observation that 
the combination therapy led to a significant G2/M phase 
arrest, but not to a significant increase in apoptotic cells 
in the transduced cell line is consistent with the view that 
low levels of p53 induce cell cycle arrest, whereas higher 
levels are needed to induce apoptosis [17]. Hence, the 
high levels of wild type p53 expressed after the sequential 
combination therapy in the parental cell line are at least 
partly responsible for the significant increase in apoptotic 
cell death compared to monotherapy. 
Previous studies have also shown a p53 independent 
effect, likely through the inhibition of the p73-MDM2 
binding or by activating E2F1 [9, 26, 27]. However, p53 
independent effects only occurred at higher concentrations 
of Nutlin-3, which could greatly increase side effects. 
We did not observe a synergistic effect when combining 
CDDP with high concentrations of Nutlin-3 in p53 
deficient/mutant cell lines (data not shown). 
An important feature of newly developed 
therapeutics is the effect on non-malignant cells, and 
in general unwanted side effects in patients, especially 
when these new drugs are combined with commonly used 
chemotherapeutics [15]. Several studies have shown a 
cytoprotective effect of Nutlin-3 in normal cells, not only 
by inducing cell cycle arrest but also by blocking BAX and 
BAK activation in mitochondria and thereby preventing 
apoptotic cell death [12, 15]. We observed a similar 
antagonistic effect in cancer cells when administrating 
higher concentrations of CDDP simultaneously with 
Nutlin-3, but not after sequential therapy, stressing the 
importance to determine if the sequential combination 
therapy is well tolerated by normal cells in vivo. 
Currently, several Nutlin-3 analogues like RG7112 
or RG7388 are in clinical trials as monotherapy or in 
combination therapy [17, 28-30]. These compounds are 
mostly tested in sarcoma patients, eg. well-differentiated 
and dedifferentiated liposarcomas, because MDM2 gene 
amplification occurs in about 20% of all cases, making 
them adequate study subjects [6, 28, 31]. However, our 
results show that other types of cancer, like NSCLC, could 
also benefit from MDM2-inhibitor combination strategies 
independent of the MDM2 expression status, by enhancing 
the expression and activation of wild type p53 in response 
to CDDP treatment. 
Our results point to an optimal combination therapy, 
being the induction of DNA damage by CDDP, followed 
by an increase in p53 levels by Nutlin-3. A lower dose of 
CDDP could be used, potentially reducing side effects for 
NSCLC patients and improving overall prognosis. This 
effect was strongly dependent on the presence of wild 
type p53. It would be interesting to extend this research 
in vivo, comparing Nutlin-3 with newly developed 
MDM2 inhibitors currently in clinical development, in 
combination with CDDP and possibly initiate a clinical 
trial. The focus should be on the ideal time point for 
the sequential administrating of both drugs in NSCLC 
patients, the administrated dose and the tumors p53 status. 
MATERIALS	AND	METHODS
Cell lines
The NSCLC adenocarcinoma cell lines used in 
this study were the parental p53 wild type A549 cell 
line (p53 WT, ECACC, Salisbury, England), and its 
isogenic derivatives A549-NTC (non-template control, 
p53 wild type) and A549-920 (p53 shRNA, lentiviral 
vector) obtained after transduction using the GIPZ 
lentiviral shRNA VGH5526-EG7157 viral particle set 
(Thermoscientific, Waltham, USA). In order to obtain 
a stably transduced cell line, cells were maintained in 
medium containing 5 μg/ml puromycin. CRL-5908 
(ATCC, Rockville, USA) was used as p53 mutant cell line 
(R273H). Cells were cultured according to the distributor’s 
instructions. 
Cells were grown as monolayers and cultures 
were maintained in exponential growth in 5% C02/95% 
air in a humidified incubator at 37°C to obtain normoxic 
conditions and in a humidifier Bactron IV anaerobic 
chamber (Shel Lab, 0% O2, 5% CO2, 95% N2) to obtain 
hypoxic conditions (<0.1% O2). Hypoxic conditions were 
initiated after first treatment. All cell lines were free from 
mycoplasma contamination.
Monotherapy
Cells were plated in 96 well plates at concentrations 
of approximately 1800 cells/well for A549, A549-NTC, 
A549-920 and 2500 cells/well for CRL-5908. Cells were 
incubated overnight and treated for 24 hours with CDDP 
(0-20 µM) or Nutlin (0-50 µM) as single agents. Forty-
eight hours after treatment, cell survival was determined 
using the sulforhodamine B (SRB) assay as previously 
described [32].
Combination therapy and criteria for synergism
The combination therapies were performed in 96 
well plates as described above. A549 cells were treated 
with CDDP (0-20 µM), combined with Nutlin-3 (5, 10, 25 
µM), either simultaneous or sequential (CDDP followed 
by Nutlin). A549-NTC, A549-920 and CRL-5908 cells 
were only treated with the most optimal combination 
therapy. Cell survival was determined by the SRB assay. 
To determine the presence of a possible synergistic 
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effect the combination index (CI) was calculated by the 
Chou-Talalay Method using the CalcuSyn software. A 
combination index CI < 1 indicates synergism, CI = 1 an 
additive effect and CI > 1 an antagonistic effect [33]. 
XCELLigence real-time cell analysis (RTCA)
Real-time monitoring of cell viability was performed 
on an xCELLigence RTCA DP instrument (ACEA 
Biosciences, San Diego, USA). A detailed description of 
this method can be found in previously published work 
from our group [34]. Cells were plated in a 16-well E-plate 
and treated with 2 μM CDDP, and previously described 
Nutlin-3 concentrations. Cell viability was monitored 
for a period of approximately 144 hours, with kinetic 
measurements programmed every 15 minutes.
RNA extraction and quantitative RT-PCR
A549 cells were plated in a 6-well plate at 
concentrations of 6.5 x 104 cells/well. Total RNA was 
extracted using the TRIzol® method (Life Technologies, 
Ghent, Belgium) after lysis. Total RNA-yield and quality 
were measured using the NanoDrop® ND-1000 (Thermo 
Scientific, Erembodegem, Belgium) and stored at -80°C. 
RT-PCR was performed using the Power SYBR 
Green RNA-to-CT 1-Step Kit (Applied Biosystems, Ghent, 
Belgium) on the LightCycler480 (Roche, Vilvoorde, 
Belgium) according to the manufacturers instructions with 
a total of 30 ng RNA. The optimal number and type of 
housekeeping genes (GAPD, RPLA13, and SDHA-1) were 
determined using the qbasePLUS software (Biogazelle, 
Zwijnaarde, Belgium). Relative gene expression levels 
were calculated according to the comparative Ct method 
using the same software and plotted against the untreated 
sample. A panel of targets was selected based on 
interesting transcription targets of p53, namely PUMA and 
BAX (apoptosis), p21 (cell cycle arrest), MDM2 (negative 
feedback loop). Primers are available on request. 
Western blot
Cells were plated in a 6-well plate as described 
above. Cells were lysed on plates in TNN buffer. After 
centrifugation (5 minutes, 800rpm) the supernatants 
containing the isolated proteins was kept at -80°C. Protein 
concentrations were determined using the Pierce® BCA 
protein assay kit (ThermoScientific). Western blot analysis 
was performed as described previously [35].
Following antibodies were used: rabbit monoclonal 
anti-p53 (1:2000, Cell Signaling Technology, Leiden, the 
Netherlands, no. 9282); mouse monoclonal anti-MDM2 
(3G9) (1:1000, Millipore, Overijse, Belgium, no. 04-
1555), rabbit monoclonal anti-p21 (1:2000, Abcam, 
Cambridge, UK, no. ab109199), rabbit monoclonal 
anti-PUMA (1:2000, Abcam no. ab33906) and rabbit 
monoclonal anti-BAX (1:2000, Abcam no. ab32503). 
Mouse monoclonal anti-β-actin was used as internal 
standard (1:5000, Sigma Aldrich, Diegem, Belgium). Anti-
mouse and anti-rabbit HRP-labeled secondary antibodies 
were used (1:2000, Cell Signaling no. 7076S and no. 
7074S) and chemiluminescent detection was performed 
using the WesternBrightTM Quantum Western blotting 
detection kit (Advansta, Temse, Belgium). 
Flow cytometry
Cells were plated in a 6-well plate as described 
above. Samples were analyzed using a FACScan flow 
cytometer (Becton Dickinson). Each sample was analyzed 
using 10.000 events/sample acquired. Data was analyzed 
using FlowJo V10. Induction of apoptotic cell death 
in the wild type A549 cell lines was investigated using 
the Annexin V-FITC apoptosis detection kit (Becton 
Dickinson Pharmingen, Erembodegem, Belgium) 
according to the manufacturers instructions. Green 
(Annexin V-FITC) and red (PI) fluorescence was analyzed 
using a FACScan flow cytometer (Becton Dickinson). 
Data was presented as dot plots (Annexin V plotted 
against PI staining). Apoptosis was determined as Annexin 
V positive cells, i.e. UR + LR. The number of apoptotic 
cells in the transduced cell lines A549-NTC and A549-
920 were determined using Annexin V-PerCP-CyTM5.5 
(BD pharmingen) due to the interference of FITC with the 
transduction control protein TurboGFP. Annexin V-PerCP-
CyTM5.5 was also used with A549 and CRL-5908 in order 
to compare the results. 
Cell cycle distribution was monitored according to 
the Vindelov method, as describe previously [36]. Data 
was presented as histograms of DNA content to determine 
cell cycle distribution (G0/G1, S and G2/M).
Statistical analysis
All experiments were performed at least three times. 
Results, if not otherwise stated, are presented as mean ± 
standard deviation (SD). Statistical significance in table 
one and two was determined using the Mann-Whitney 
U test between each group and the untreated control. 
Statistical significance for apoptosis, cell cycle arrest and 
mRNA levels was determined by a two-way ANOVA test, 
followed by Dunnett’s post hoc test for the comparison 
with the untreated sample or CDDP treated sample, using 
SPSS 22.
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